SEGMENT INFORMATION

9 Months Ended

Jun. 30, 2021

SEGMENT INFORMATION

SEGMENT INFORMATION

5.           SEGMENT INFORMATION

The Company operates in two principal segments - research services and research products. The Services segment provides research and development support on a contract basis directly to pharmaceutical companies. The Products segment provides liquid chromatography, electrochemical and physiological monitoring products to pharmaceutical companies, universities, government research centers and medical research institutions.  The accounting policies of these segments are the same as those described in the

summary of significant accounting policies found in Note 2 to the Consolidated Financial Statements in the Company’s annual report on Form 10-K for the fiscal year ended September 30, 2020.

	Three Months Ended				Nine Months Ended
	June 30,				June 30,
	2021		2020		2021		2020
Revenue:
Service	$	21,924	$	14,852	$	56,858	$	42,185
Product		968		913		2,671		2,510
	$	22,892	$	15,765	$	59,529	$	44,695
Operating Income (Loss)
Service	$	3,868	$	2,460	$	10,942	$	6,393
Product		61		23		202		(447)
Corporate		(5,632)		(2,960)		(13,354)		(7,638)
	$	(1,703)	$	(477)	$	(2,210)	$	(1,692)
Interest expense		(449)		(382)		(1,163)		(1,085)
Other income		1		1		180		13
Loss before income taxes	$	(2,151)	$	(858)	$	(3,193)	$	(2,764)